QURE
uniQure N.V.
$22.43
-2.94%
2026-10-23
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Key Fundamentals
Forward P/E
-12.78
EPS (TTM)
$-4.06
ROE
-157.6%
Revenue Growth (YoY)
11.0%
Profit Margin
0.0%
Debt/Equity
170.40
Price/Book
8.18
Beta
0.94
Market Cap
$2.65B
Avg Volume (10D)
1.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$51.72
60D Low
$20.33
Avg Volume
2.0M
Latest Close
$22.43
Get breakout alerts for QURE
Sign up for Breakout Scanner to receive daily notifications when QURE triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
uniQure N.V. (QURE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors QURE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. QURE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.